Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record.

Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System

Open access
Fam, Neil P., von Bardeleben, Ralph Stephan, Hensey, Mark, Kodali, Susheel K., Smith, Robert L., Hausleiter, Jörg, Ong, Geraldine, Boone, Robert, Ruf, Tobias, George, Isaac, Szerlip, Molly, Näbauer, Michael, Ali, Faeez M., Moss, Robert, Bapat, Vinayak, Schnitzler, Katharina, Kreidel, Felix, Ye, Jian, Deva, Djeven P., Mack, Michael J., Grayburn, Paul A., Peterson, Mark D., Leon, Martin B., Hahn, Rebecca T., Webb, John G. · 2021 · JACC: Cardiovascular Interventions

Abstract

OBJECTIVES The purpose of this observational first-in-human experience was to investigate the feasibility and safety of the EVOQUE tricuspid valve replacement system and its impact on short-term clinical outcomes. BACKGROUND Transcatheter tricuspid intervention is a promising option for selected patients with severe tricuspid regurgitation (TR). Although transcatheter leaflet repair is an option for some, transcatheter tricuspid valve replacement (TTVR) may be applicable to a broader population. METHODS Twenty-five patients with severe TR underwent EVOQUE TTVR in a compassionate-use experience. The primary outcome was technical success, with NYHA (NYHA) functional class, TR grade, and major adverse cardiac and cerebrovascular events assessed at 30-day follow-up. RESULTS All patients (mean age 76 ± 3 years, 88% women) were at high surgical risk (mean Society of Thoracic Surgeons risk score 9.1 ± 2.3%), with 96% in NYHA functional class III or IV. TR etiology was predominantly functional, with mean tricuspid annular diameter of 44.8 ± 7.8 mm and mean tricuspid annular plane systolic excursion of 16 ± 2 mm. Technical success was 92%, with no intraprocedural mortality or conversion to surgery. At 30-day follow-up, mortality was 0%, 76% of patients were in NYHA functional class I or II, and TR grade was ≤2+ in 96%. Major bleeding occurred in 3 patients (12%), 2 patients (8%) required pacemaker implantation, and 1 patient (4%) required dialysis. CONCLUSIONS This first-in-human experience evaluating EVOQUE TTVR demonstrated high technical success, acceptable safety, and significant clinical improvement. Larger prospective studies are needed to confirm durability and safety and the impact on long-term clinical outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcin.2020.11.045

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 196

Metadata

Authors
Fam, N. P., von Bardeleben, R. S., Hensey, M., Kodali, S. K., Smith, R. L., Hausleiter, J., Ong, G., Boone, R., Ruf, T., George, I., Szerlip, M., Näbauer, M., Ali, F. M., Moss, R., Bapat, V., Schnitzler, K., Kreidel, F., Ye, J., Deva, D. P., Mack, M. J., Grayburn, P. A., Peterson, M. D., Leon, M. B., Hahn, R. T., & Webb, J. G.
Venue
JACC: Cardiovascular Interventions
Publisher
Elsevier BV
Published
2021-03
Volume
14
Issue
5
Pages
501-511
ISSN
  • 1876-7605 (ISSN-L)
  • 1936-8798
OpenAlex
W3126552591
Cited by
196
References
0
FWCI
23.37
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System. https://app.cochat.ai/papers/10.1016/j.jcin.2020.11.045
The paper
Fam, N. P., von Bardeleben, R. S., Hensey, M., Kodali, S. K., Smith, R. L., Hausleiter, J., Ong, G., Boone, R., Ruf, T., George, I., Szerlip, M., Näbauer, M., Ali, F. M., Moss, R., Bapat, V., Schnitzler, K., Kreidel, F., Ye, J., Deva, D. P., . . . Webb, J. G. (2021). Transfemoral Transcatheter Tricuspid Valve Replacement With the EVOQUE System. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2020.11.045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.